The Forgotten Law Behind Prescription Price Drops: A Reality Check on Trump’s Claims

The latest numbers from the Labor Department show a 0.8% drop in U.S. prescription drug prices in July, and a 3.1% decrease year-over-year – the steepest drop since 1963. President Donald Trump attributes this trend to his “most favored nation” deals with pharmaceutical firms and the TrumpRx website.

However, experts argue that this narrative oversimplifies the situation. The real story behind these price drops lies in a largely forgotten law enacted during President Joe Biden’s time in office – the 2022 Inflation Reduction Act (IRA). This law allows Medicare to negotiate with pharmaceutical companies over the cost of top-selling prescription drugs in the program.

The IRA may have gone unnoticed at the time of its passage, but its effects are starting to become apparent. For the first-time, Medicare can haggle with drugmakers, and this change likely played a significant role in driving down aggregate prices. Experts believe that it has a more substantial impact than any benefits from Trump’s “most favored nation” deals.

Market competition appears to be a major factor in the declining price trend. When big blockbuster products face generic competition, their prices fall – as seen with biosimilar drugs like Humira and Stelara. However, attributing the entire drop to market forces alone oversimplifies the situation. The actual impact of Trump’s “most favored nation” deals remains unclear due to a lack of transparency in the contracts with drug companies.

The White House touts its TrumpRx website as a valuable resource for price transparency, but experts point out that it’s unclear how many Americans are actually using this service. Many brand-name drugs featured on the site have cheaper alternatives – either through insurance or generic versions sold elsewhere. The claim that TrumpRx has generated $700 million in savings for patients is unverifiable due to a lack of transparent data.

Even as prescription prices drop, experts warn that consumers aren’t necessarily seeing these savings in their budgets. This is because the Labor Department’s figures measure what pharmacies are paid by insurers and consumers, not directly what consumers pay themselves. Insurers often absorb much of the cost, and patients’ out-of-pocket expenses depend on a variety of factors.

Higher health spending and federal policy changes continue to drive up insurance premiums and out-of-pocket costs for many Americans – potentially offsetting any benefits from declining prescription prices. A price measure like the consumer price index can’t adequately capture these complexities.

The real story behind declining prescription prices lies in nuanced, incremental changes that have a lasting impact on prescription prices – such as the IRA’s Medicare negotiation provisions. Policymakers and leaders should focus on addressing systemic issues driving up healthcare costs overall rather than taking credit for fleeting price drops. Only then can we truly see the benefits of declining prescription prices translate into tangible relief for consumers.